FORA Capital LLC Takes Position in Boston Scientific Corporation $BSX

Key Points

• FORA Capital LLC acquired 50,983 shares of Boston Scientific Corporation, valued at approximately $5,143,000, during the first quarter.
• CEO Michael F. Mahoney sold 164,443 shares for over $17 million, resulting in a significant decrease in his ownership stake.
• The company reported $5.06 billion in revenue for the last quarter, exceeding analysts' expectations and showing a year-over-year revenue increase of 22.8%.

FORA Capital LLC purchased a new position in Boston Scientific Corporation (NYSE:BSX - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 50,983 shares of the medical equipment provider's stock, valued at approximately $5,143,000.

A number of other institutional investors also recently modified their holdings of BSX. Y.D. More Investments Ltd bought a new stake in Boston Scientific during the 1st quarter valued at $27,000. Investment Management Corp VA ADV bought a new position in Boston Scientific during the fourth quarter valued at about $25,000. Colonial Trust Co SC lifted its holdings in Boston Scientific by 1,625.0% during the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 260 shares during the last quarter. Sunbeam Capital Management LLC purchased a new stake in shares of Boston Scientific in the fourth quarter worth about $26,000. Finally, Ameriflex Group Inc. purchased a new stake in shares of Boston Scientific in the fourth quarter worth about $31,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Robert W. Baird increased their price target on shares of Boston Scientific from $117.00 to $123.00 and gave the company an "outperform" rating in a research report on Thursday, July 24th. Citigroup reissued a "buy" rating and set a $125.00 price objective (up previously from $119.00) on shares of Boston Scientific in a research report on Thursday, May 22nd. Barclays boosted their target price on Boston Scientific from $125.00 to $133.00 and gave the stock an "overweight" rating in a research report on Thursday, July 24th. Jefferies Financial Group reissued a "hold" rating on shares of Boston Scientific in a report on Monday, July 21st. Finally, Leerink Partnrs upgraded Boston Scientific to a "strong-buy" rating in a research note on Monday, June 16th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $117.50.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director Yoshiaki Fujimori sold 2,901 shares of the company's stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the sale, the director owned 2,081 shares in the company, valued at $222,646.19. This represents a 58.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Edward J. Ludwig sold 4,000 shares of the company's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the sale, the director directly owned 18,479 shares of the company's stock, valued at approximately $1,959,328.37. This trade represents a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 345,029 shares of company stock worth $35,976,603 over the last quarter. 0.50% of the stock is currently owned by insiders.

Boston Scientific Stock Down 0.2%

BSX stock traded down $0.19 during trading on Friday, reaching $105.56. 4,066,860 shares of the company traded hands, compared to its average volume of 7,483,689. The business has a 50 day simple moving average of $104.45 and a 200 day simple moving average of $102.17. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. Boston Scientific Corporation has a 12 month low of $79.53 and a 12 month high of $108.94. The company has a market capitalization of $156.41 billion, a price-to-earnings ratio of 62.83, a price-to-earnings-growth ratio of 2.55 and a beta of 0.66.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm had revenue of $5.06 billion during the quarter, compared to analysts' expectations of $4.89 billion. During the same period last year, the business posted $0.62 earnings per share. The company's revenue for the quarter was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.